FindTrial
Sign In

EPZ-5676

DRUG2 trials

Sponsors

Epizyme, Inc.

Conditions

Acute LeukemiasAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaLeukemiaMyelodysplastic SyndromeMyeloproliferative Disorders

Phase 1

A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
CompletedNCT01684150
Epizyme, Inc.Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome +1
Start: 2012-09-30End: 2016-02-29Updated: 2024-03-26
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
CompletedNCT02141828
Epizyme, Inc.Acute Leukemias, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia +1
Start: 2014-05-31End: 2016-06-30Updated: 2023-06-18

Related Papers

Structural variants involving <i>MLLT10</i> fusion are associated with adverse outcomes in pediatric acute myeloid leukemia
Blood Advances2024-02-027 citations
High-Density CRISPR Scan Identifies Functional Regions of DOT1L That Mediate Therapeutic Response in MLL-r Leukemia
Blood2018-11-292 citations
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
Blood2018-05-03442 citations
Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia
Blood2016-12-0285 citations
A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition
Blood2015-12-0347 citations
Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition
Blood2015-12-0313 citations
Abstract C12: Identification of biomarkers and pathways associated with response to the DOT1L inhibitor Pinometostat (EPZ-5676) in MLL-r leukemia
Molecular Cancer Therapeutics2015-12-011 citations
The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia
Blood2014-12-0644 citations
Pediatric Dose Determinations for the Phase I Study of the DOT1L Inhibitor, EPZ-5676, in MLL-r Acute Leukemia: Leveraging Early Clinical Data in Adults through Physiologically-Based Pharmacokinetic Modeling
Blood2014-12-064 citations
MDR1 Mediated Drug Resistance to a Histone Methyltansferase Inhibitor (KMT)
Blood2014-12-06